Valbenazine significantly reduced involuntary movements associated with tardive dyskinesia in patients with primary mood disorders, at both 6 weeks and 48 weeks after beginning the treatment, according to a published analysis.
Increasing physical activity appears to boost mood and energy in adults—especially so in those with bipolar I disorder, according to a study published online in JAMA Psychiatry.
High-dose antipsychotic use in children and young adults without psychosis is associated with an increased risk of unexpected death, according to a study published online in JAMA Psychiatry.
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
Use the links here to see all of our coverage of sessions, speakers, and posters at Psych Congress 2018.
ORLANDO, Fla.—A friendly debate between 2 thought leaders followed by a vote at Psych Congress 2018 exhibited the divide that persists on a controversial topic in mental health.
Ode to Dr. Quinn Leslie who has paved the path to accepting non-perfectionism.
Clinical pearls from the Psych Congress annual meeting.
Bipolar disorder affects approximately 2% to 3% of the population and is the sixth leading cause of disability worldwide.
This short (less than 8 minutes), learner-friendly video is designed to introduce the Mood Disorder Questionnaire (MDQ) and get you ready to use it today.
Terence Ketter, MD, Professor of Psychiatry at Stanford University in Stanford, California, discusses how clinicians can identify which patients with bipolar disorder will be treatment-resistant.
Terence Ketter, MD, Professor of Psychiatry at Stanford University in Stanford, California, discusses some tools which are underutilized in treatment of patients with treatment-resistant bipolar disorder.